Tenders Are Invited For Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Pharmaceuticals (Open House Procedure)

Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Pharmaceuticals (Open House Procedure). The Procurement Requirements Of Ohv 2026 Include All Drugs With The Active Ingredients Named In Appendix 3 To The Conditions Of Participation (So-Called List Of Active Ingredients And Deadlines). Contracts Can Be Concluded For Individual Active Ingredients. The Procurement Requirements Were Not Divided Into Lots. This Is An Open House Procedure. To The Extent That Wording Is Used In This Announcement That Indicates The Division Of Procurement Requirements Into One Or More Lots, This Is Solely Due To The Specifications Of This Announcement Form. In This Context, Reference Is Made To The Non-Applicability Of Procurement Regulations Described At The Beginning Of Section 2.1. The Aok Has Once Again Expanded The Procurement Requirements Of The Open House Procedure, Which Was First Announced In The Announcement Oj Eu 680694-2025, And The Further Announcements To The Effect That Agreements In Accordance With Section 130A Paragraph 8 Sgbv Should Also Be Concluded For Medicinal Products With The Following Active Ingredients Within The Framework Of This Open House Procedure: Cinnarizine + Dimenhydrinate (Sequence No. 33 Of The Appendix 3 To The Conditions Of Participation), Eltrombopag (Sequence No. 34 Of Appendix 3 To The Conditions Of Participation), Fampridine (Sequence No. 35 Of Appendix 3 To The Conditions Of Participation), Tiotropium Bromide-1 Water 3.12 Μg (Sequence No. 36 Of Appendix 3 To The Conditions Of Participation). Annex 3 To The Conditions Of Participation Has Therefore Been Adapted Accordingly And Is Available To Interested Companies After Free Registration Together With The Other Procedural Documents On The Procurement Platform (See Section 5.1.11 Of This Follow-Up Announcement). The Aok Reserves The Right To Adjust The Procurement Requirements Of This Open House Process As The Process Continues. The Conditions Of Participation Contain Further Information On A Possible Adjustment Of The Procurement Requirements (Section A.I.4.1). Contracts For Medicinal Products With The Above-Mentioned Active Ingredients Will Be Closed With Effect From April 1, 2026 At The Earliest. All Discount Agreements Concluded As Part Of This Open House Procedure End On December 31, 2027. To Start Discount Contracts With The Above-Mentioned Active Ingredients On April 1, 2026, Interested Companies Must Submit A Complete Offer In Accordance With The Participation Documents Exclusively In Electronic Form Via The Communication Area Of ​​The Procurement Platform By February 20, 2026 At The Latest. It Is Possible To Conclude A Discount Contract At A Later Date Than April 1, 2026 On The First Of Each Month. The Offers Must Be Submitted In Full No Later Than The 20Th Of The Month Before The Intended Start Of The Contract. For All Contracts To Be Concluded As Part Of This Open House Procedure, The Last Possible Contract Start Date Is December 1St, 2027. Offers For This Contract Start Must Be Received By October 20, 2027 At The Latest. The Aok Specifies The Content Of The Discount Agreement As Binding For All Potential Contractual Partners. Negotiation